LITOR
(Atorvastatin) is indicated as an adjunct
to diet (see tables below) for reduction of elevated total cholesterol
(total-c), LDL cholesterol (LDL-c), apoliprotein B and triglycerides in patients
with primary hypercholesterolemia including familial hypercholesterolemia
(Heterozygous variant) or combined (mixed) hyperlipidemia corresponding to type
II a and II b of the Fredrickson classification.
|
Table(1) Classification of LDL, Total, and HDL
Cholesterol (mg/dL) |
|
LDL cholesterol |
|
|
< 100 |
Optimal |
|
100 – 129 |
Near optimal/above optimal |
|
130 – 159 |
Borderline high |
|
160 – 189 |
High |
|
≥ 190 |
Very high |
|
Total Cholesterol |
|
|
<200 |
Desirable |
|
200-239 |
Borderline high |
|
≥240 |
High |
|
HDL Cholesterol |
|
|
<40 |
Low |
|
≥60 |
High |
-
LITOR (Atorvastatin) also indicated to
reduce total-c and LDL-c in patient with homozygous familial
hypercholesterolemia as an adjunct to other lipid lowering treatment e.g. LDL
apheresis.
|
Table (2): LDL Cholesterol Goals and Cutpoints for
the Therapeutic Lifestyle Changes (TLC) and Drug Therapy in
Different Risk Categories. |
|
Risk Category |
LDL Goal |
LDL Level at Which to Initiate Therapeutic Lifestyle
Changes (TLC)
|
LDL Level
at Which to
Consider Drug
Therapy |
|
CHD1 or CHD Risk
Equivalents
(10-year risk >20%) |
<
100 mg/dL |
≥
100 mg/dL |
≥
130 mg/dL
(100-129 mg/dL
drug optional) |
|
2+ Risk Factors *
(10-year risk ≤20%) |
<130 mg/dL |
≥
130 mg/dL |
10-year risk <10-20%:
≥130 mg/dL |
|
10-year risk <10%:
≥160 mg/dL |
|
0-1 Risk Factor |
<160 mg/dL |
≥
160 mg/dL |
≥190 mg/dL
(160-189 mg/dL
LDL-lowering drug
optional) |
1
CHD: Coronary heart disease
*
Major risk factors (exclusive of LDL cholesterol) that modify LDL goals :
-Diabetes
mellitus.
-Cigarette
smoking
-Hypertension
(BP ≥140/90 mmHg or on antihypertensive medication)
-Family
history of premature CHD (CHD in male first degree relative >55 years; CHD in
female first degree relative >65 years)
-
Age (men ≥45
years; women ≥55 years)
